fda glp-1 news november 2025 Beyond the Headlines: Warning Letters to Compounders Scam warning: GLP-1 shoppers warned

The authors noted, 2.4 mg of semaglutide once weekly was associated with sustained, clinically relevant reduction in body weight. Participants lost far more weight than those on placebo, the kind of weight loss previously seen only after bariatric surgery

Using a single characterized GLP-1S preparation allows consistent evaluation of incretin effects in research settings without variability from undefined mixtures

Discontinuation might also be necessary if you experience persistent side effects that don't improve with dose adjustments or extended use

What about the scary headlines

We would not accept a 2% treatment rate for any other deadly disease